Company profile

Septerna, Inc.

NASDAQ:SEPNBiotechnology: Pharmaceutical Preparations

Clinical trials (2)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT07433179phase1recruiting2026-03-042027-02-01Septerna, Inc.A Study to Evaluate Single and Multiple Doses of SEP-479 in Healthy Adult Participants
NCT07069036phase1completed2025-07-152025-12-18Septerna, Inc.A Study to Evaluate Single and Multiple Doses of SEP-631 in Healthy Adult Volunteers

FDA applications (0)

No records yet.